Position statement on the management of pregnancy in sickle cell disease.

Mimi Yue, Kylie Mason, Shelley Rowlands, Zane Kaplan, Debra Kennedy, Giselle Kidson-Gerber

Abstract readPractice Guideline

In one paragraph

Guideline in The Australian & New Zealand journal of obstetrics & gynaecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Evaluating Reproductive Health Recommendations in CPGs for Sickle Cell Disease: An Umbrella Review.Clinical and public health guidelines · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mimi YueDepartment of Haematology, Mater Health Service, Brisbane, Queensland, Australia.

Kylie MasonDepartment of Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Shelley RowlandsDepartment of Maternal Fetal Medicine, Royal Women's Hospital, Melbourne, Victoria, Australia.

Zane KaplanMonash Haematology, Monash Health, Melbourne, Victoria, Australia.

Debra KennedyRoyal Hospital for Women, Randwick Campus, Sydney, New South Wales, Australia.

Giselle Kidson-GerberSchools of Medicine and Women's and Children's Health, Prince of Wales Hospital and Royal Hospital for Women Clinical School, University of NSW, Sydney, New South Wales, Australia.ORCID 0000-0001-5834-0890

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sickle cell disease (SCD) is a hereditary haemoglobinopathy which causes multi-organ dysfunction. Pregnancies in SCD are high risk with significant maternal and fetal morbidity and mortality, including vaso-occlusive crises, thrombosis, anaemia, placental insufficiency, fetal growth restriction, preterm birth and medication effects. High level evidence on this topic is lacking. The Australian Sickle Cell Disease Working Group has reviewed international guidelines on this topic and provide an up-to-date and structured approach to the pre-conception, antenatal, birth and post-partum management of these women. Early and comprehensive multidisciplinary care involving experienced clinicians is recommended.

Indexed as

Anemia, Sickle CellPregnancy Complications, HematologicAustraliaFemaleHumansPregnancyPrenatal Careanaemiapregnancypregnancy complicationsprenatal caresickle cell

Identifiers

PMID39333023

DOI10.1111/ajo.13888

PMCPMC12099178

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.